Renaissance Technologies LLC trimmed its position in Syndax Pharmaceuticals Inc (NASDAQ:SNDX) by 19.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 42,300 shares of the company’s stock after selling 10,200 shares during the quarter. Renaissance Technologies LLC’s holdings in Syndax Pharmaceuticals were worth $297,000 at the end of the most recent reporting period.
Several other hedge funds have also recently modified their holdings of SNDX. The Manufacturers Life Insurance Company raised its position in shares of Syndax Pharmaceuticals by 266.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 10,566 shares of the company’s stock worth $151,000 after acquiring an additional 7,686 shares in the last quarter. Rhumbline Advisers bought a new position in shares of Syndax Pharmaceuticals in the 2nd quarter worth $103,000. Spark Investment Management LLC bought a new position in shares of Syndax Pharmaceuticals in the 2nd quarter worth $198,000. Bank of New York Mellon Corp raised its position in shares of Syndax Pharmaceuticals by 72.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 80,372 shares of the company’s stock worth $564,000 after acquiring an additional 33,892 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Syndax Pharmaceuticals in the 2nd quarter worth $368,000. Institutional investors and hedge funds own 64.38% of the company’s stock.
Several research firms have recently commented on SNDX. Zacks Investment Research lowered Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 10th. Citigroup reduced their price target on Syndax Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, October 11th. HC Wainwright reduced their price target on Syndax Pharmaceuticals to $23.00 and set a “buy” rating for the company in a research report on Friday, October 26th. ValuEngine lowered Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Morgan Stanley lowered Syndax Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $6.00 price target for the company. in a research report on Monday, October 29th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $18.20.
Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Monday, November 5th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.08. Syndax Pharmaceuticals had a negative return on equity of 91.11% and a negative net margin of 3,185.75%. The company had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.38 million. Equities analysts predict that Syndax Pharmaceuticals Inc will post -3.03 earnings per share for the current fiscal year.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.
Read More: What Is An Exchange-Traded Fund (ETF)?
Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals Inc (NASDAQ:SNDX).
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.